This study is evaluating newer global blood clotting tests and their use and reproducibility in patients with haemophilia A and haemophilia B. Haematological Disorders Haemophilia
Conditions
Interventions
Participants will be asked to provide one or two additional aliquots of blood (5.4 ml citrated blood) for this study whilst undergoing routine clinical assessment. No additional blood draws will be re
a ‘baseline’ blood sample is taken for testing either factor VIII or factor IX levels.
Patients who require prophylactic treatment (regular infusions) routinely have two blood samples taken in clini
Sponsors
Oxford University Hospitals NHS Trust
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Participant is willing and able to give informed consent for participation in the study 2. Male, aged 18 years or above 3. Diagnosed with haemophilia A or B
Exclusion criteria
Exclusion criteria: Concomitant use of pro-haemostatic agents such as tranexamic acid or anti-coagulant agent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is to find a normal range for thrombin generation and ROTEM measures in patients with haemophilia as measured by evaluating a blood sample at time 0 hours. The blood will be tested for thrombin generation and for whole blood viscoelastometric measures which are both global measures of coagulation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome will be to correlate the laboratory tests with clinical outcome. Thrombin generation measures and ROTEM measures will be compared at time 0 hours and correlated with the number of joint bleeds that a patient has as measured using an annualised bleeding rate. | — |
Countries
United Kingdom
Contacts
Public ContactNicola Curry
Outcome results
None listed